Repligen Corporation (NASDAQ:RGEN) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Analysts collectively rate Repligen “Moderate Buy,” with 12 buy, three strong-buy, two hold and one sell recommendation. The average 12-month price target is $166.43.
• Repligen exceeded quarterly expectations, reporting $0.54 EPS versus a $0.45 consensus and revenue of $204.13 million, up 11.9% year over year. Analysts expect approximately $2.06 EPS for the current year.
• The stock opened at $163.90, near the analyst consensus target, while institutional investors own a substantial 97.64% stake; CFO Jason K. Garland recently sold $106,285 worth of shares.

Shares of Repligen Corporation (NASDAQ:RGEN - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the eighteen ratings firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, twelve have issued a buy recommendation and three have issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $166.4286.

A number of equities analysts have recently weighed in on RGEN shares. Canaccord Genuity Group lowered their price target on Repligen from $165.00 to $145.00 and set a "hold" rating for the company in a report on Monday, April 20th. Wolfe Research initiated coverage on shares of Repligen in a report on Tuesday, June 2nd. They issued an "outperform" rating and a $145.00 price objective on the stock. JPMorgan Chase & Co. upped their target price on shares of Repligen from $165.00 to $175.00 and gave the company an "overweight" rating in a research report on Wednesday, July 29th. Royal Bank Of Canada initiated coverage on shares of Repligen in a research note on Thursday, May 14th. They set an "outperform" rating and a $160.00 target price for the company. Finally, Evercore reiterated an "outperform" rating and set a $160.00 price target on shares of Repligen in a research report on Monday, July 6th.

Repligen Stock Performance

RGEN opened at $163.90 on Monday. The stock has a market capitalization of $9.25 billion, a PE ratio of 224.52, a P/E/G ratio of 2.98 and a beta of 1.03. Repligen has a one year low of $100.99 and a one year high of $175.77. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.64 and a current ratio of 9.05. The business's 50 day moving average price is $138.44 and its 200 day moving average price is $131.09.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.45 by $0.09. Repligen had a return on equity of 5.30% and a net margin of 5.29%.The company had revenue of $204.13 million during the quarter, compared to analysts' expectations of $201.59 million. During the same quarter last year, the firm earned $0.26 earnings per share. The firm's quarterly revenue was up 11.9% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. As a group, equities research analysts expect that Repligen will post 2.06 EPS for the current year.

Insider Activity at Repligen

In related news, CFO Jason K. Garland sold 733 shares of the stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $145.00, for a total transaction of $106,285.00. Following the completion of the transaction, the chief financial officer owned 19,359 shares of the company's stock, valued at approximately $2,807,055. This trade represents a 3.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.60% of the company's stock.

Institutional Trading of Repligen

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RGEN. AQR Capital Management LLC acquired a new stake in shares of Repligen in the first quarter valued at $262,000. Jones Financial Companies Lllp raised its holdings in shares of Repligen by 3,850.6% in the 1st quarter. Jones Financial Companies Lllp now owns 6,400 shares of the biotechnology company's stock valued at $814,000 after buying an additional 6,238 shares during the period. Goldman Sachs Group Inc. lifted its stake in Repligen by 16.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 141,994 shares of the biotechnology company's stock worth $18,067,000 after acquiring an additional 20,375 shares in the last quarter. Bank of Nova Scotia lifted its stake in Repligen by 88.0% during the 2nd quarter. Bank of Nova Scotia now owns 31,747 shares of the biotechnology company's stock worth $3,951,000 after acquiring an additional 14,860 shares in the last quarter. Finally, Daiwa Securities Group Inc. lifted its stake in Repligen by 29.7% during the 2nd quarter. Daiwa Securities Group Inc. now owns 31,194 shares of the biotechnology company's stock worth $3,880,000 after acquiring an additional 7,148 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

Repligen Company Profile

Repligen Corporation NASDAQ: RGEN is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen's offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company's core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source